Single-chain Fragment variable antibody targeting cholecystokinin-B receptor for pain reduction.

However, the duration of efficacy various antibodies is variable in the literature. Pharmacokinetic analysis of an Epidermal Growth Factor Receptor (EGFR) scFv in a mouse tumor model indicated it was only evident in the blood up to 6 h, but its specificity of bind to the target and effectiveness for solid tumor volume reduction was highly significant ( Kim et al., 2014 ).

also in 132,142 other papers